Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Advanced Endometrial Cancer Clinical Trial

Official title:
Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.

Status Recruiting

Clinical Trial Summary

This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase. The formal trial includes 60 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The purpose is to evaluate efficacy and safety of TQB2450 injection combined with chemotherapy ± anlotinib hydrochloride capsules for first-line treatment and maintenance treatment of patient with advanced endometrial cancer or sarcoma of uterus, and explore biomarkers related to efficacy, mechanism of action, safety and/or pathological mechanisms, the surgical conversion rate. ORR is the primary endpoint.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05481645
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Xiaojun Chen, Doctor
Phone	021-33189900
Email	cxjlhjj@163.com
Status	Recruiting
Phase	Phase 2
Start date	August 22, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04574284` - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Phase 2
Withdrawn	`NCT06046274` - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Phase 2
Recruiting	`NCT05112991` - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05106127` - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Phase 2
Completed	`NCT01289041` - BKM120 as Second-line Therapy for Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05077215` - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3